Jun Wu1, Dong-Xun Zhou1, Tian-Tian Wang1, Dao-Jian Gao1, Bing Hu2. 1. Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, 225 Changhai Road, Shanghai, China. 2. Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, 225 Changhai Road, Shanghai, China. drhubing@aliyun.com.
Abstract
BACKGROUND: Endotherapy with plastic stent (PS) placement is the main modality for treating benign biliary strictures (BBSs). Fully covered self-expandable metal stents (FCSEMSs) are being increasingly used for BBS management, with high stricture resolution. However, traditional metal tents are associated with high migration, causing treatment failure. METHODS: We investigated the efficacy and safety of a new FCSEMS for postsurgical BBS treatment and compared these parameters between the FCSEMS and PS treatment through retrospective analysis. The primary outcome measurements included stricture resolution, stricture recurrence, and complications. RESULTS: In total, 69 patients were included, of whom 32 underwent FCSEMS treatment and 37 underwent PS treatment. The technical success rate and the number of endoscopic retrograde cholangiopancreatography procedures were similar between the groups. The median stenting duration was 5.2 months (range 1.5-15.3) in the FCSEMS group and 10.7 months (range 2.5-22.6) in the PS group (P < 0.01). The stents removal rate was 96.9% in the FCSEMS group and 94.6% in the PS group. The stricture resolution rate based on intention-to-treat analysis was 83.8% in the PS group and 84.4% (27/32) in the FCSEMS group (P = 0.947), whereas the rates from per-protocol analysis were 88.6% (31/35) and 87.1% (27/31), respectively (P = 0.574). Early and late complications were similar between the groups. The median follow-up time was 43 months (range 13-71). The stricture recurrence rate was 11.1% (3/27) in the FCSEMS group and 16.1% (5/31) in the PS group (P = 0.435). CONCLUSIONS: The new FCSEMS and the PS approach showed similar efficacy and safety in postsurgical BBS treatment. However, the FCSEMS required fewer procedural steps and shorter stenting time, making it an effective alternative modality.
BACKGROUND: Endotherapy with plastic stent (PS) placement is the main modality for treating benign biliary strictures (BBSs). Fully covered self-expandable metal stents (FCSEMSs) are being increasingly used for BBS management, with high stricture resolution. However, traditional metal tents are associated with high migration, causing treatment failure. METHODS: We investigated the efficacy and safety of a new FCSEMS for postsurgical BBS treatment and compared these parameters between the FCSEMS and PS treatment through retrospective analysis. The primary outcome measurements included stricture resolution, stricture recurrence, and complications. RESULTS: In total, 69 patients were included, of whom 32 underwent FCSEMS treatment and 37 underwent PS treatment. The technical success rate and the number of endoscopic retrograde cholangiopancreatography procedures were similar between the groups. The median stenting duration was 5.2 months (range 1.5-15.3) in the FCSEMS group and 10.7 months (range 2.5-22.6) in the PS group (P < 0.01). The stents removal rate was 96.9% in the FCSEMS group and 94.6% in the PS group. The stricture resolution rate based on intention-to-treat analysis was 83.8% in the PS group and 84.4% (27/32) in the FCSEMS group (P = 0.947), whereas the rates from per-protocol analysis were 88.6% (31/35) and 87.1% (27/31), respectively (P = 0.574). Early and late complications were similar between the groups. The median follow-up time was 43 months (range 13-71). The stricture recurrence rate was 11.1% (3/27) in the FCSEMS group and 16.1% (5/31) in the PS group (P = 0.435). CONCLUSIONS: The new FCSEMS and the PS approach showed similar efficacy and safety in postsurgical BBS treatment. However, the FCSEMS required fewer procedural steps and shorter stenting time, making it an effective alternative modality.
Authors: P Sauer; F Chahoud; D Gotthardt; W Stremmel; K-H Weiss; M Büchler; P Schemmer; J Weitz; A Schaible Journal: Endoscopy Date: 2012-02-27 Impact factor: 10.093
Authors: Djuna L Cahen; Anne-Marie M van Berkel; Daphne Oskam; Erik A J Rauws; Gerrit Jan Weverling; Kees Huibregtse; Marco J Bruno Journal: Eur J Gastroenterol Hepatol Date: 2005-01 Impact factor: 2.566
Authors: James H Tabibian; Emad H Asham; Steven Han; Sammy Saab; Myron J Tong; Leonard Goldstein; Ronald W Busuttil; Francisco A Durazo Journal: Gastrointest Endosc Date: 2010-03 Impact factor: 9.427
Authors: Carola Haapamäki; Leena Kylänpää; Marianne Udd; Outi Lindström; Juha Grönroos; Arto Saarela; Harri Mustonen; Jorma Halttunen Journal: Endoscopy Date: 2015-01-15 Impact factor: 10.093
Authors: John A Kasher; James G Corasanti; Paul R Tarnasky; Lee McHenry; Evan Fogel; John Cunningham Journal: Gastrointest Endosc Date: 2011-04-05 Impact factor: 9.427